<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111484</url>
  </required_header>
  <id_info>
    <org_study_id>H-18020494</org_study_id>
    <nct_id>NCT04111484</nct_id>
  </id_info>
  <brief_title>Adrenomedullin Effect on Migraine Without Patients</brief_title>
  <official_title>Adrenomedullins Headache Inducing Effects on Migraine Without Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AM is a naturally occurring peptide in the body and consists of 52 amino acids. AM belongs to
      the calcitonin gene-related peptide (CGRP) superfamily and has several structural,
      physiological and pharmacological similarities to CGRP, intermdine and amylin. In a
      randomized double-blind, placebo controlled cross-over design 20 migraine patients without
      aura recruited to receive infusion of adrenomedullin or placebo (saline).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AM is a naturally occurring peptide in the body and consists of 52 amino acids. AM belongs to
      the calcitonin gene-related peptide (CGRP) superfamily and has several structural,
      physiological and pharmacological similarities to CGRP, intermdine and amylin. In a
      randomized double-blind, placebo controlled cross-over design 20 migraine patients without
      aura recruited to receive infusion of adrenomedullin or placebo (saline).

      A pilot study on healthy volunteers were conducted to determine tolerable dose of
      adrenomedullin to the main study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2019</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study participants and investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine incidance after infusion of adrenomedullin compared to placebo</measure>
    <time_frame>0-12 hours</time_frame>
    <description>A standard headache questionnaire will be used to register headache intensity and migraine associated symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache intensity</measure>
    <time_frame>0-12 hours</time_frame>
    <description>Headache intensity will be measured using Visual analogue scale (0 = no pain -10 = worst pain )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in puls, MAP and facial flushing</measure>
    <time_frame>0-90 minutes</time_frame>
    <description>After infusion of adrenomedullin compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>Adrenomedullin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will received 19.9 picomol/kg/min of adrenomedullin over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adrenomedullin</intervention_name>
    <description>Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.</description>
    <arm_group_label>Adrenomedullin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-60 years old

          -  50-100 kg

          -  migraine without aura according International Headache Classification Disorders 3rd
             edition

        Exclusion Criteria:

          -  Tension-type headaches more than 5 days a month on average over the past year.

          -  All other primary headache forms.-

          -  Headache later than 48 hours before the start of the trial.

          -  Daily intake of medicines of all kinds except oral contraception.

          -  Taking any medicine later than 4 times the plasma half-life of that drug (on the day
             of the trial), except oral contraception.

          -  Pregnant or breastfeeding women.

          -  Headache on the day of the trial or later than 48 hours before the administration of
             the trial drug / placebo

          -  Migraines within 3 days before the trial date.

          -  Anamnestic information or clinical signs (on the day of inclusion):

          -  Hypertension (systolic blood pressure&gt; 150 mmHg and / or diastolic blood pressure&gt; 100
             mmHg)

          -  Hypotension (systolic blood pressure &lt;90 mm Hg and / or diastolic blood pressure &lt;50
             mmHg)

          -  Cardiovascular diseases of all kinds, including cerebrovascular diseases.

          -  Anamnestic or clinical signs of mental illness or abuse.

          -  Patients with glaucoma or prostate hyperplasia

          -  Anamnestic or clinical signs of illness of any kind that the investigating physician
             considers relevant for participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Hashmat Ghanizada, MD</investigator_full_name>
    <investigator_title>MD, PhD-Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

